ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL

Post author:admERY
Post published:September 28, 2017
Post category:Newsroom

ERYTECH today announced the determination of the recommended pivotal Phase 3 dosing from its U.S. Phase 1 dose escalation study with eryaspase (GRASPA®) in first line treatment of adult ALL patients.

You Might Also Like

ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia

ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018

ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes.